Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indomethacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 11/20 | 0.65 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.65 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.65 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.65 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | PTGES | O14684 | 1/20 | 0.65 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acemetacin SCHEMBL10532791 | 0.93 | PTGS2 (0.68) | PTGS2AKR1C3AKR1C2HIF1APTGS1 | |
| Indomethacin SCHEMBL6034048 | 0.93 | PTGS2 (0.56) | PTGS2AKR1C3AKR1C2HIF1APTGS1 | |
| Indomethacin SCHEMBL28072579 | 0.82 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2HIF1APTGS1 | |
| Indomethacin SCHEMBL28285479 | 0.81 | PTGS2 (0.88) | PTGS2AKR1C3AKR1C2HIF1APTGS1 | |
| Indomethacin SCHEMBL27521872 | 0.81 | PTGS2 (0.92) | PTGS2AKR1C3AKR1C2HIF1APTGS1 | |
| Indomethacin SCHEMBL29353712 | 0.81 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2HIF1APTGS1 | |
| Indomethacin SCHEMBL29525957 | 0.81 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2HIF1APTGS1 | |
| Indomethacin SCHEMBL3518614 | 0.81 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2HIF1APTGS1 | |
| Indomethacin SCHEMBL9300 | 0.81 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2HIF1APTGS1 | |
| Clometacin SCHEMBL10532953 | 0.81 | PTGS2 (0.51) | PTGS2PTGS1LMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119784-A1 | METHOD FOR PREPARING MICRONEEDLE LOADED WITH DRUG MICROCRYSTAL AND MICRONEEDLE PREPARED USING SAME | 中国科学院理化技术研究所 | 2024-06-13 | — | — | WO | disclosed |
| CN-109481422-B | Graphene oxide electrothermal film transdermal patch | 广西中医药大学 | 2022-11-11 | — | — | CN | disclosed |
| EP-1997811-B1 | Indazole, benzoxazole and pyrazolopyridine derivatives as P38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-101759645-B | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC | 2014-06-25 | — | — | CN | disclosed |
| EP-1997809-B1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8518983-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1997810-B1 | Indazoles, benzotriazoles and N-analogs thereof as p38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1981851-B1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8044083-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20060264431-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006122230-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| US-7135575-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| CN-1784396-A | p38 inhibitors and methods of their use | ARRAY BIOPHARMA INC (US) | 2006-06-07 | — | — | CN | disclosed |
| EP-1606283-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | ARRAY BIOPHARMA INC. | 2004-09-09 | — | — | US | disclosed |
| US-6498274-B1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED (GB) | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | MAPK1, MAPK3, MAP3K1 | PTGS2 853/4885PTGS1 376/4885AKR1C3 2582/4885 |
| US-20060264431-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | PTGS2 326/4885PTGS1 159/4885AKR1C3 1737/4885 |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | PTGS2 262/4885PTGS1 143/4885AKR1C3 2048/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | PTGS2 262/4885PTGS1 143/4885AKR1C3 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.